Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.56 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.53 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18623620 | 1.00 | SIGMAR1 (0.56) | SIGMAR1OPRM1OPRD1OPRK1MRGPRX2 | |
| SCHEMBL12324824 | 0.87 | SIGMAR1 (0.73) | SIGMAR1OPRM1OPRD1OPRK1MRGPRX2 | |
| SCHEMBL12267534 | 0.87 | SIGMAR1 (0.73) | SIGMAR1OPRM1OPRD1OPRK1MRGPRX2 | |
| SCHEMBL12716235 | 0.87 | SIGMAR1 (0.73) | SIGMAR1OPRM1OPRD1OPRK1MRGPRX2 | |
| SCHEMBL15706497 | 0.84 | SIGMAR1 (0.58) | SIGMAR1OPRM1OPRD1OPRK1MRGPRX2 | |
| SCHEMBL15706493 | 0.83 | SIGMAR1 (0.53) | SIGMAR1OPRM1OPRD1OPRK1MRGPRX2 | |
| SCHEMBL18604354 | 0.83 | SIGMAR1 (0.56) | SIGMAR1OPRM1OPRD1OPRK1MRGPRX2 | |
| SCHEMBL17252062 | 0.83 | SIGMAR1 (0.56) | SIGMAR1OPRM1OPRD1OPRK1MRGPRX2 | |
| SCHEMBL15706422 | 0.83 | SIGMAR1 (0.56) | SIGMAR1OPRM1OPRD1OPRK1MRGPRX2 | |
| SCHEMBL17252063 | 0.83 | SIGMAR1 (0.56) | SIGMAR1OPRM1OPRD1OPRK1MRGPRX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975854-B2 | Benzomorphan analogs and use thereof | PURDUE PHARMA L.P. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170073313-A1 | BENZOMORPHAN ANALOGS And Use Thereof | PURDUE PHARMA L.P. | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073313-A1 | BENZOMORPHAN ANALOGS And Use Thereof | OPRL1, OPRD1, OPRK1 | SIGMAR1 7/4885OPRM1 4/4885OPRD1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.